By InvitationEarly Phase 1

Comparison of Eohilia With Dupixent on Esophagus Diameter in Patients With Eosinophilic Esophagitis.

United States60 participantsStarted 2026-02-04

Plain-language summary

The purpose of this study is to compare Eosinophilic Esophagitis treatments Eohilia with Dupixent in their effects on diameter and scarring of the esophagus.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Provision of signed and dated informed consent form
✓. Stated willingness to comply with all study procedures and availability for the duration of the study
✓. Male or female, aged ≥18 year of age at Mayo Clinic Rochester or Mayo Clinic Scottsdale at time of informed consent
✓. Have a documented diagnosis of EoE per standard guidelines
✓. Have histologically active EoE (defined as a peak eosinophil count \>15 eosinophils per high-power field; eos/hpf)
✓. Weight ≥40 kg
✓. Ability to take injectable or oral medication and be willing to adhere to the study intervention regimen
✓. For females of reproductive potential: use of highly effective contraception for at least 1 month prior to screening and agreement to use such a method during study participation and for an additional 12 weeks after the end of dupilumab or budesonide suspension administration. Willingness to complete pregnancy tests during study visits and at end of study.

Exclusion criteria

✕. Inability to provide informed consent
✕. Pregnancy or lactation
✕. Contraindication to performing upper endoscopy
✕. Known allergic reactions to components of dupilumab or budesonide suspension
✕. Non-EoE eosinophilic GI diseases (EGIDs) or hypereosinophilic disorders
✕. Prior esophageal surgery, coagulopathy or esophageal varices
✕. Known achalasia, crohn's disease, ulcerative colitis, celiac disease
✕. Child-Pugh Class C liver disease

What they're measuring

Esophageal diameter

Timeframe: from enrollment until up to 14 weeks

Trial details

NCT IDNCT07358234

SponsorMayo Clinic

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2027-12

View on ClinicalTrials.gov More Eosinophilic Esophagitis (EoE) trials